SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
Portfolio Pulse from
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is set to launch REZENOPY®, a naloxone nasal spray for opioid overdose treatment, in collaboration with Kindeva Drug Delivery. This follows FDA approval in April 2024.
March 06, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is launching REZENOPY®, a naloxone nasal spray for opioid overdose, in collaboration with Kindeva Drug Delivery. This product, approved by the FDA in April 2024, addresses a critical market need.
The launch of REZENOPY® represents a significant product introduction for SCIENTURE, addressing the opioid crisis with a newly FDA-approved treatment. This collaboration with Kindeva could enhance SCIENTURE's market position and revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100